Rare Cancers Conference

The Rare Cancers Conference 2026 is a CME/CE-accredited educational program taking place in San Francisco, aimed at enhancing the diagnosis and management of rare and orphan malignancies. This multidisciplinary conference is significant due to the complexity and heterogeneity of rare cancers, and it gathers experts from various fields including medical oncology, hematology, pathology, genomics, surgery, and radiation oncology. The primary focus of the conference is to address critical gaps in knowledge and care related to rare cancers. Attendees will have the opportunity to delve into innovations in molecular diagnostics, next-generation sequencing (NGS), biomarker identification, and precision oncology approaches that are reshaping treatment paradigms for rare tumors. Participants will engage in discussions surrounding emerging targeted therapies, immunotherapy strategies, and clinical trial opportunities, with a strong emphasis on improving access to cutting-edge treatments. Through case-based discussions and expert-led sessions, attendees will acquire practical tools to navigate diagnostic uncertainties and apply evidence even in low-data settings. The conference also aims to foster collaboration across multiple disciplines to optimize patient outcomes while addressing challenges such as delayed diagnosis, limited treatment guidelines, and disparities in access to specialized care. The conference is tailored for medical oncologists, hematologist-oncologists, advanced practice providers, oncology pharmacists, multidisciplinary care team members, researchers, fellows, and healthcare professionals interested in rare cancers and precision oncology. Participants will be equipped to apply advanced diagnostic and molecular testing approaches, integrate genomic and biomarker data into personalized treatment strategies, evaluate emerging clinical evidence, develop multidisciplinary care plans, identify clinical trial opportunities, and recognize the challenges and disparities in managing rare cancers. The organizing body, Binaytara, is a 501(c)(3) not-for-profit organization with 17 years of experience in advocating, educating, and innovating to improve cancer care.